WP
ANIP icon

Woodline Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Woodline Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-166,448
Closed -$11.1M – 920
2025
Q1 		$11.1M Buy
+166,448
New +$9.94M 0.07% 343
2024
Q4 		– Sell
-156,488
Closed -$9.34M – 924
2024
Q3 		$9.34M Buy
+156,488
New +$9.55M 0.08% 309

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Woodline Partners's ANIP Position: Q2 2025 in Review

Woodline Partners sold out of ANI Pharmaceuticals (ANIP) in Q2 2025, closing a stake of 166,448 shares — an estimated $11.1M sold.

Woodline Partners first reported a position in ANIP in Q3 2024 and held it in 2 quarters. The position peaked at $11.1M in Q1 2025. 232 funds tracked by Wall St. Rank hold ANIP as of Q2 2025.

  • Woodline Partners reported no remaining ANI Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Woodline Partners sold 166,448 ANI Pharmaceuticals shares in Q2 2025, an estimated $11.1M.
  • Woodline Partners first reported a position in ANI Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Woodline Partners's ANI Pharmaceuticals position peaked at $11.1M in Q1 2025.
  • 232 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2025.

Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.